Cloricromen hydrochloride

Synonyms: Cloricromene hydrochloride; AD6 hydrochloride
Cloricromen (Cloricromene) hydrochloride 是一种具有口服活性的血小板抑制剂,可抑制血栓烷 B2 (thromboxane B2) 释放、β-血栓球蛋白 (β-thromboglobulin) 生成及血栓形成,并可抑制 LPS (MS-X54539) 诱导的 NF-κB 活化、氧化活性及 TNF-α 表达,在休克和外周缺血动物模型中表现出保护活性,可用于心肌缺血/再灌注损伤及缺血性脑血管病的相关研究。
产品编号: MS-M45300 纯度: 99.82% CAS No.: 74697-28-2 分子式: C20H27Cl2NO5 分子量: 432.34
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Cloricromen (Cloricromene) hydrochloride 是一种具有口服活性的血小板抑制剂,可抑制血栓烷 B2 (thromboxane B2) 释放、β-血栓球蛋白 (β-thromboglobulin) 生成及血栓形成,并可抑制 LPS (MS-X54539) 诱导的 NF-κB 活化、氧化活性及 TNF-α 表达,在休克和外周缺血动物模型中表现出保护活性,可用于心肌缺血/再灌注损伤及缺血性脑血管病的相关研究。

生物实验数据

生物活性 Cloricromen (Cloricromene) hydrochloride is an orally active platelet inhibitor that inhibits thromboxane B2 release, β-thromboglobulin production, and thrombosis, suppresses LPS (MS-X54539)-induced NF-κB activation, oxidative activity, and TNF-α expression, exhibits protective activity in animal models of shock and peripheral ischemia, and can be used in research related to myocardial ischemia/reperfusion injury and ischemic cerebrovascular disease.
体外研究
(In Vitro)

Cloricromen (1-50 μM; 10 min pre-incubation before 24 h LPS exposure) hydrochloride 可强效抑制脂多糖诱导大鼠肺泡巨噬细胞释放 TNF-α,其 IC50 为 5.9 μM;且不会引发细胞毒性。
Cloricromen (10 μM; 10 min pre-incubation before 2 h LPS exposure) hydrochloride 可在大鼠肺泡巨噬细胞中抑制脂多糖诱导的 TNF-α mRNA 表达,提示其作用机制为转录前调控。
Cloricromen (1-50 μM; 10 min pre-incubation before 15 min LPS exposure) hydrochloride 可通过靶向激活过程而非直接结合 DNA,以剂量依赖性方式抑制脂多糖诱导的大鼠肺泡巨噬细胞中 NF-κB 激活。
Cloricromen (10 μM; 10 min pre-incubation before 5 min LPS exposure) hydrochloride 对脂多糖诱导的大鼠肺泡巨噬细胞中 PKC-βII 转位仅具有轻微作用。
Cloricromen (hydrochloride) (10 μM; 10 min pre-incubation before LPS exposure) hydrochloride 可显著抑制脂多糖诱导的大鼠肺泡巨噬细胞氧化活性。

RT-PCR

Cell Line: rat alveolar macrophages
Concentration: 10 μM
Incubation Time: 10 min pre-incubation before 2 h LPS exposure
Result: Inhibited LPS-induced TNF-α mRNA expression by ~60%.
体内研究
(In Vivo)

Cloricromen (30-300 μg/kg/min;静脉注射;持续输注;从缺血前 15 分钟至再灌注 2 小时) Cloricromen 可在心肌缺血再灌注损伤的兔中诱导剂量依赖性的心脏保护作用。
Cloricromene hydrochloride 通过抑制 TNF-α 产生、提高存活率并逆转相关血流动力学和血液学异常,对脂多糖诱导的雄性 Sprague-Dawley 大鼠内毒素休克起到保护作用。
Cloricromene hydrochloride 可减小遭受缺血再灌注损伤的雄性 Sprague-Dawley 大鼠的心肌梗死面积。
Cloricromene (0.25-0.50 mg/kg;静脉注射;持续输注;最长 70 分钟) hydrochloride 可减轻家兔心肌缺血再灌注损伤。

Animal Model: New Zealand white rabbits (male, 2-3 kg, myocardial ischaemia-reperfusion model via 1 hour left coronary artery occlusion followed by 2 hours reperfusion)
Dosage: 30; 300 μg/kg/min
Administration: i.v.; continuous infusion; from 15 minutes pre-occlusion through 2-hour reperfusion
Result: Reduced infarct size to 40.8% of the area at risk.
Significantly reduced myeloperoxidase activity in infarcted myocardial tissue.
Showed no attenuation of occlusion-induced ST-segment elevation.
Detected no inhibition of ex vivo platelet aggregation induced by ADP or collagen.
Caused no significant changes in mean arterial blood pressure, pressure-rate index, left ventricular systolic pressure, or heart rate relative to controls.
Significantly reduced myeloperoxidase activity in infarcted myocardial tissue.
Significantly reduced occlusion-induced ST-segment elevation to 0.08 mV at 20 minutes post-occlusion and returned to basal levels by 1 hour post-occlusion.
Inhibited ex vivo platelet aggregation, with collagen-induced aggregation reduced to 57% at end of occlusion and 13% after 2-hour reperfusion, and ADP-induced aggregation reduced to 74% at end of occlusion and 53% after 2-hour reperfusion.
Caused a slight, non-significant decrease in mean arterial blood pressure, a significant decrease in left ventricular systolic pressure at end of occlusion, and a significant increase in heart rate at end of reperfusion, with no change in pressure-rate index.
Animal Model: New Zealand white rabbits (pathogen-free, 2.5-3.5 kg)
Dosage: 3.6 μg/kg/min; 7.1 μg/kg/min (for transient ST elevations); total 0.25-0.50 mg/kg
Administration: i.v.; continuous infusion; up to 70 minutes
Result: Reversed transient ST-segment elevations in 3 out of 4 affected rabbits.
Showed no significant difference in chemiluminescence between anterior and posterior ventricular walls.
Achieved an anterior/posterior wall chemiluminescence ratio of 0.95.
Resulted in an overall myocardial-cell injury score of 1.4.
Preserved myocyte subcellular architecture with only mild or moderate mitochondrial edema.
Maintained well-preserved capillary structure with occasional mild/moderate endothelial luminal protrusions.
Observed focal subendocardial necrosis in 3 out of 10 treated rabbits.
Prevented reperfusion arrhythmias.
性状 固体
颜色 White to off-white

化学信息

分子量 432.34
分子式 C20H27Cl2NO5
CAS No. 74697-28-2
别名 Cloricromene hydrochloride; AD6 hydrochloride

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (231.30 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.3130 mL11.5650 mL23.1299 mL57.8249 mL
5 mM0.4626 mL2.3130 mL4.6260 mL11.5650 mL
10 mM0.2313 mL1.1565 mL2.3130 mL5.7825 mL
15 mM0.1542 mL0.7710 mL1.5420 mL3.8550 mL
20 mM0.1156 mL0.5782 mL1.1565 mL2.8912 mL
25 mM0.0925 mL0.4626 mL0.9252 mL2.3130 mL
30 mM0.0771 mL0.3855 mL0.7710 mL1.9275 mL
40 mM0.0578 mL0.2891 mL0.5782 mL1.4456 mL
50 mM0.0463 mL0.2313 mL0.4626 mL1.1565 mL
60 mM0.0385 mL0.1927 mL0.3855 mL0.9637 mL
80 mM0.0289 mL0.1446 mL0.2891 mL0.7228 mL
100 mM0.0231 mL0.1156 mL0.2313 mL0.5782 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础